Treatment News : Possible Interaction Between Isentress and Intelence?

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2009

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 15, 2009

Possible Interaction Between Isentress and Intelence?

Intelence (etravirine) may lower blood levels of Isentress (raltegravir) in some people, according to a series of case reports published in the April 27 issue of AIDS.

Isentress and Intelence, an integrase inhibitor and a non-nucleoside reverse transcriptase inhibitor, have become popular medication options for people who are heavily treatment experienced. Thus far, small studies in HIV-negative volunteers have not demonstrated that one lowers or raises blood levels of the other, but there are not substantial amounts of data involving drug combinations of both antiretrovirals in treatment-experienced HIV-positive patients.

Contrary to the studies in HIV-negative volunteers, Amélie Ménard, MD, from the Sainte Marguerite University Hospital, in Marseille, France and her colleagues report four cases of HIV-positive heavily treatment-experienced patients having significant drug interactions. In three of the cases, the patients started Isentress and Intelence at the same time. In the remaining case, the patient started taking Intelence after having been on Isentress for a while.

In all four cases, blood levels of Isentress were reduced significantly, while blood levels of Intelence stayed in the normal range. Ménard and her colleagues comment that HIV levels in the four patients did not drop as much as would have been expected after starting new regimens involving these drugs, and they believe that the reduced Isentress blood levels are the likely culprits.

The authors conclude that standard drug interaction studies involving HIV-negative volunteers may not always accurately predict what will happen in people with HIV, especially treatment-experienced patients. They recommend that providers explore therapeutic drug monitoring options to measure Isentress blood levels in patients who combine Isentress and Intelence, and that further study of these two drugs is warranted.

Search: Isentress, raltegravir, Intelence, emtricitabine, drug interactions, blood levels, Amélie Ménard

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.